TANDEM DIABETES CARE INC (TNDM) Stock Fundamental Analysis
USA - NASDAQ:TNDM - US8753722037 - Common Stock
18.61 USD
+1.08 (+6.16%)
18.88 USD
+0.27 (+1.45%)
Taking everything into account, TNDM scores 2 out of 10 in our fundamental rating. TNDM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TNDM have multiple concerns. While showing a medium growth rate, TNDM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TNDM has reported negative net income.
In the past year TNDM has reported a negative cash flow from operations.
TNDM had negative earnings in 4 of the past 5 years.
TNDM had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
TNDM has a Return On Assets (-23.25%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -152.95%, TNDM is doing worse than 67.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.25% | ||
| ROE | -152.95% | ||
| ROIC | N/A |
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 53.23%, TNDM perfoms like the industry average, outperforming 47.09% of the companies in the same industry.
In the last couple of years the Gross Margin of TNDM has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TNDM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNDM has more shares outstanding
The number of shares outstanding for TNDM has been increased compared to 5 years ago.
The debt/assets ratio for TNDM is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.34, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
TNDM has a Altman-Z score of 0.34. This is comparable to the rest of the industry: TNDM outperforms 47.09% of its industry peers.
A Debt/Equity ratio of 2.37 is on the high side and indicates that TNDM has dependencies on debt financing.
TNDM has a Debt to Equity ratio of 2.37. This is amonst the worse of the industry: TNDM underperforms 84.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.34 |
ROIC/WACCN/A
WACC7.15%
2.3 Liquidity
A Current Ratio of 2.44 indicates that TNDM has no problem at all paying its short term obligations.
TNDM has a Current ratio of 2.44. This is comparable to the rest of the industry: TNDM outperforms 47.09% of its industry peers.
A Quick Ratio of 1.90 indicates that TNDM should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.90, TNDM perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.44 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.53% over the past year.
Looking at the last year, TNDM shows a quite strong growth in Revenue. The Revenue has grown by 17.87% in the last year.
The Revenue has been growing by 21.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)17.87%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%2.16%
3.2 Future
Based on estimates for the next years, TNDM will show a very strong growth in Earnings Per Share. The EPS will grow by 21.31% on average per year.
The Revenue is expected to grow by 9.26% on average over the next years. This is quite good.
EPS Next Y-45.82%
EPS Next 2Y17.43%
EPS Next 3Y23.45%
EPS Next 5Y21.31%
Revenue Next Year9.78%
Revenue Next 2Y9.7%
Revenue Next 3Y9.31%
Revenue Next 5Y9.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TNDM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNDM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TNDM's earnings are expected to grow with 23.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.43%
EPS Next 3Y23.45%
5. Dividend
5.1 Amount
No dividends for TNDM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
18.61
+1.08 (+6.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners121.11%
Inst Owner Change-5.45%
Ins Owners0.7%
Ins Owner Change12.36%
Market Cap1.26B
Revenue(TTM)1.01B
Net Income(TTM)-203.37M
Analysts71.33
Price Target20.82 (11.88%)
Short Float %13.82%
Short Ratio4.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.74%
Min EPS beat(2)-18.66%
Max EPS beat(2)3.18%
EPS beat(4)2
Avg EPS beat(4)20.77%
Min EPS beat(4)-18.66%
Max EPS beat(4)104.27%
EPS beat(8)5
Avg EPS beat(8)15.83%
EPS beat(12)5
Avg EPS beat(12)-40.04%
EPS beat(16)5
Avg EPS beat(16)-129.71%
Revenue beat(2)1
Avg Revenue beat(2)1.01%
Min Revenue beat(2)-1.1%
Max Revenue beat(2)3.12%
Revenue beat(4)3
Avg Revenue beat(4)4.09%
Min Revenue beat(4)-1.1%
Max Revenue beat(4)9.97%
Revenue beat(8)6
Avg Revenue beat(8)4.19%
Revenue beat(12)6
Avg Revenue beat(12)1.79%
Revenue beat(16)8
Avg Revenue beat(16)1.24%
PT rev (1m)-4.12%
PT rev (3m)-40.14%
EPS NQ rev (1m)1.27%
EPS NQ rev (3m)-16.56%
EPS NY rev (1m)2.25%
EPS NY rev (3m)-47.29%
Revenue NQ rev (1m)-1.03%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.46 | ||
| P/tB | 9.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS14.9
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.25% | ||
| ROE | -152.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.23% | ||
| FCFM | N/A |
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
F-Score4
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 360.22% | ||
| Cap/Sales | 6.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.44 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z | 0.34 |
F-Score4
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)341.43%
Cap/Depr(5y)300.44%
Cap/Sales(3y)6.42%
Cap/Sales(5y)5.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y-45.82%
EPS Next 2Y17.43%
EPS Next 3Y23.45%
EPS Next 5Y21.31%
Revenue 1Y (TTM)17.87%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%2.16%
Revenue Next Year9.78%
Revenue Next 2Y9.7%
Revenue Next 3Y9.31%
Revenue Next 5Y9.26%
EBIT growth 1Y34.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.52%
EBIT Next 3Y43.44%
EBIT Next 5Y30.41%
FCF growth 1Y-47.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.98%
OCF growth 3Y-39.87%
OCF growth 5Y-10.38%
TANDEM DIABETES CARE INC / TNDM FAQ
What is the ChartMill fundamental rating of TANDEM DIABETES CARE INC (TNDM) stock?
ChartMill assigns a fundamental rating of 2 / 10 to TNDM.
What is the valuation status for TNDM stock?
ChartMill assigns a valuation rating of 1 / 10 to TANDEM DIABETES CARE INC (TNDM). This can be considered as Overvalued.
Can you provide the profitability details for TANDEM DIABETES CARE INC?
TANDEM DIABETES CARE INC (TNDM) has a profitability rating of 1 / 10.
How financially healthy is TANDEM DIABETES CARE INC?
The financial health rating of TANDEM DIABETES CARE INC (TNDM) is 2 / 10.